1. Trunet PF, Mueller P, Bhatnagar AS, Dickes I, Monnet G, White G (1993) Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20267, in healthy male subjects. J Clin Endocrinol Metab 77:319–323
2. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596–2606. Erratum in: J Clin Oncol 2001;19:3302
3. Femara package insert. East Hanover, NJ; Novartis Pharmaceuticals Corp., 2005
4. Palshof T, Mouridsen HT, Daehnfeldt JL (1980) Adjuvant endocrine therapy of breast cancer—a controlled clinical trial of oestrogen and anti-oestrogen: preliminary results of the Copenhagen breast cancer trials. Recent Results Cancer Res 71:185–189
5. Awada A, Cardoso F, Fontaine C, Dirix L, De Grève J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Ressayre-Djaffer C, Piccart M (2004) A phase Ib study of the mTOR inhibitor RAD001 (everolimus) in combination with letrozole (Femara®), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole. Breast Cancer Res Treat 88(Suppl 1):S234. Abstract 6043